AstraZeneca's Datroway boosts survival in advanced breast cancer trial

Core Insights - AstraZeneca's precision drug Datroway has shown improved overall survival and progression-free survival in patients with advanced breast cancer compared to chemotherapy when administered early during treatment [1] Group 1 - Datroway is a precision drug developed by AstraZeneca [1] - The drug demonstrated better outcomes in overall survival and progression-free survival in clinical trials [1] - The trial results indicate the potential of Datroway as a more effective treatment option for advanced breast cancer [1]